[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643213":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":53,"collaborators":26,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":26,"eligibilityCriteria":61,"healthyVolunteers":58,"sex":62,"minAge":26,"maxAge":26,"enrollmentInfo":63,"targetDuration":26,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":26,"overallStatus":74,"whyStopped":26,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"liposomal bupivacaine group","EXPERIMENTAL","Patients will receive an intercostal nerve block with a mixture of liposomal bupivacaine and bupivacaine hydrochloride after surgery.",[13],"Drug: LB\u002FBH intercostal nerve block",{"label":15,"type":16,"description":17,"interventionNames":18},"control group","ACTIVE_COMPARATOR","Patients will receive an intercostal nerve block with bupivacaine hydrochloride after surgery.",[19],"Drug: BH intercostal nerve block",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","LB\u002FBH intercostal nerve block","Patients will receive an intercostal nerve block with a mixture of liposomal bupivacaine and bupivacaine hydrochloride immediately after lung transplantation.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"BH intercostal nerve block","Patients will receive an intercostal nerve block with bupivacaine hydrochloride immediately after lung transplantation.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Min Yan","CONTACT","13757118632","zryanmin@zju.edu.cn",[38],{"facility":39,"status":26,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"The Second Affiliated Hospital of Zhejiang University anesthesiology department","Hangzhou","Zhejiang","310000","China","CN",{"type":46,"coordinates":47},"Point",[48,49],120.16142,30.29365,{"lat":49,"lon":48},[52],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},{"type":54,"investigatorFullName":33,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Cheif of the Department of Anesthesiology, Second Affiliated Hospital of Zhejiang University","100643213","phase-4-the-effect-of-bupivacaine-liposomes-on-postoperative-pain-in-lung-transplant-patients-after-intercostal-nerve-block-a-randomized-controlled-study-100643213",false,"NCT07641647","The Effect of Bupivacaine Liposomes on Postoperative Pain in Lung Transplant Patients After Intercostal Nerve Block: a Randomized Controlled Study","Inclusion Criteria:\n\n* Patients with end-stage lung disease undergoing bilateral lung transplantation; Age \\>18 years; Expected discontinuation of mechanical ventilation within 48 hours after surgery; The patient or legally authorized representative signs the informed consent form and agrees to participate in the study and follow-up.\n\nExclusion Criteria:\n\n* Body mass index ≤18 kg\u002Fm² or ≥35 kg\u002Fm²; Allergy or contraindication to local anesthetics; Preoperative tracheal intubation or requirement for extracorporeal life support; Expected use of other types of nerve block; Active systemic infection or infection at the planned block site; Severe hepatic insufficiency; Severe renal impairment; Chronic pain, neuropathic pain, long-term use of analgesics, or use of other psychotropic medications; Preoperative cognitive impairment, cerebrovascular disease, or history of psychiatric disorders; Severe coagulation dysfunction; Concomitant surgery during the same operative session; Pregnant or breastfeeding women.","ALL",{"count":64,"type":65},88,"ESTIMATED","INTERVENTIONAL",[68],"PHASE4","The goal of this clinical trial is to evaluate the efficacy and safety of liposomal bupivacaine for postoperative analgesia in adult patients undergoing lung transplantation. The main questions it aims to answer are:\n\nDoes liposomal bupivacaine reduce postoperative opioid consumption after lung transplantation? Does liposomal bupivacaine relieve postoperative pain without increasing adverse events?\n\nResearchers will compare patients receiving liposomal bupivacaine combined with bupivacaine hydrochloride with patients receiving bupivacaine hydrochloride alone to see whether liposomal bupivacaine provides better postoperative analgesia and reduces opioid requirements after lung transplantation.\n\nParticipants will:\n\nReceive lung transplantation under standard perioperative care. Receive intercostal nerve block with either liposomal bupivacaine combined with bupivacaine hydrochloride or bupivacaine hydrochloride alone.\n\nBe assessed for postoperative opioid consumption, pain scores, recovery-related outcomes, and adverse events after surgery.",[71,72,73],"Lung Transplantation","Pain Management","Liposomal Bupivacaine","NOT_YET_RECRUITING","2026-06-07",{"date":77,"type":78},"2026-06-11","ACTUAL",{"date":80,"type":65},"2026-07-01",{"date":82,"type":65},"2028-07-01",{"name":5,"class":6},1]